BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Other: No intervention
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 151
- Registration Number
- NCT01585974
Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Phase 3
Completed
- Conditions
- Colorectal Neoplasms
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 204
- Registration Number
- NCT01584830
Xarelto [SPAF] Post-marketing Surveillance in Japan
Completed
- Conditions
- Brain Ischemia
- Interventions
- Drug: Rivaroxaban(Xarelto, BAY59-7939)
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 11310
- Registration Number
- NCT01582737
A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
Phase 2
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: BAY94-9027
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 145
- Registration Number
- NCT01580293
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
Phase 1
Terminated
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 43
- Registration Number
- NCT01573338
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT01565746
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 44
- Registration Number
- NCT01561794
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 205
- Registration Number
- NCT01557127
A 3-fold Crossover Bioequivalence Study Between Glucobay ODT (Orally Disintegrating Tablet) 100 mg and Glucobay Standard Tablet 100 mg
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2013-06-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 34
- Registration Number
- NCT01554631
Efficacy of a Single Dose of Aspirin vs. Acetaminophen in Tension Type Headache
Phase 3
Terminated
- Conditions
- Headache
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT01552798
- Locations
- 🇺🇸
Westside Family Medical Center, Kalamazoo, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath